{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:21:16Z","timestamp":1792718476497,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2007,6,11]],"date-time":"2007-06-11T00:00:00Z","timestamp":1181520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Salivary duct carcinoma (SDC) is an aggressive tumor of the head and neck with a poor prognosis. The objective was to study SDC and recommend the use of trastuzumab as adjuvant therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective chart review of patients seen between 1993 and 2006 was performed. Tumor specimens were examined for HER\u20102 protein overexpression via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 7 patients with SDC, 57% had tumors arising in the parotid gland, the majority having facial nerve paralysis, 71% with nodal disease, and 43% having recurrence. All samples were HER\u20102 positive on IHC. Three patients had FISH\u2010positive tumors, recurrent disease, and recieved trastuzumab therapy; 1 of the 3 died after 20 months and a second has shown disappearance of metastatic disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Trastuzumab is effective in treating HER\u20102\u2010positive breast cancer. Given immunohistochemical similarities between SDC and ductal carcinoma of the breast, patients with FISH\u2010positive <jats:italic>HER\u20102\/neu<\/jats:italic> SDC should be considered for trastuzumab therapy. \u00a9 2007 Wiley Periodicals, Inc. Head Neck 2007<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.20614","type":"journal-article","created":{"date-parts":[[2007,6,12]],"date-time":"2007-06-12T05:01:38Z","timestamp":1181624498000},"page":"907-912","source":"Crossref","is-referenced-by-count":133,"title":["Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy"],"prefix":"10.1002","volume":"29","author":[{"given":"Vishad","family":"Nabili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Bhuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel A.","family":"Sercarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian S.","family":"Head","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00301495"},{"key":"e_1_2_5_3_2","unstructured":"BarnesELJr.Tumor pathology of the head and neck. In: 106th Semi\u2010Annual CTTR Seminar: Tumors of the Head and Neck Pittsburgh PA;1999. pp8\u201312."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0090075"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2002.s.016"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00008"},{"key":"e_1_2_5_7_2","first-page":"100","article-title":"Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Skalova A","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.094"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199703)19:2<126::AID-HED7>3.0.CO;2-6"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<223::AID-CNCR1>3.0.CO;2-N"},{"key":"e_1_2_5_11_2","first-page":"1033","article-title":"Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma","volume":"11","author":"Kapadia S","year":"1998","journal-title":"Mod Pathol"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200004000-00014"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.127.9.1075"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.9050"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1159\/000066201"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000066200"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S69"},{"key":"e_1_2_5_19_2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/ajhp\/57.22.2063","article-title":"Pharmacology and therapeutic use of trastuzumab in breast cancer","volume":"57","author":"Treish I","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00404-4"},{"issue":"5","key":"e_1_2_5_21_2","first-page":"20","article-title":"Clinical trials of single\u2010agent trastuzumab (Herceptin)","volume":"27","author":"Baselga J","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.719"},{"issue":"3","key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0093-7754(02)70125-5","article-title":"Trastuzumab\/chemotherapy combinations in metastatic breast cancer","volume":"29","author":"Ligibel JA","year":"2002","journal-title":"Semin Oncol"},{"issue":"6","key":"e_1_2_5_24_2","first-page":"26","article-title":"Ongoing and planned adjuvant trials with trastuzumab","volume":"27","author":"Perez EA","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"issue":"11","key":"e_1_2_5_26_2","first-page":"53","article-title":"Her2\/neu as a therapeutic target in non\u2010small cell lung cancer, prostate cancer, and ovarian cancer","volume":"27","author":"Agus D","year":"2000","journal-title":"Semin Oncol"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0636"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.20614","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.20614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T04:14:40Z","timestamp":1697602480000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.20614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,11]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1002\/hed.20614"],"URL":"https:\/\/doi.org\/10.1002\/hed.20614","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,11]]}}}